Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 16, 2008. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in their interests in the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider share transactions rather than a financial performance report.
Material Changes
The material change reported is the increase in shareholdings for five specific individuals due to the reinvestment of dividends under a Single Company ISA on October 9, 2008. The shares were purchased at a price of £11.30 per ordinary share. The specific changes are:
- Mr A P Witty: 5 shares
- Mr J S Heslop: 7 shares
- Mr S M Bicknell: 32 shares
- Mr E J Gray: 6 shares
- Mr D S Redfern: 6 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly adheres to the requirements of Disclosure and Transparency Rule 3.1.4R(1)(a) regarding the notification of director transactions.
Key Facts for Investor Verification
- Transaction Date: October 9, 2008.
- Share Price: £11.30 per ordinary share.
- Transaction Type: Dividend reinvestment via Single Company ISA.
- Parties Involved: Five directors or connected persons (Witty, Heslop, Bicknell, Gray, Redfern).
- Reporting Date: October 16, 2008.